Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1372 participants
OBSERVATIONAL
2007-09-30
2013-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Effectiveness of Botulinum Toxin in Elderly Patients With Dementia and Muscle Stiffness
NCT02212119
BOTOX® (onabotulinumtoxinA) Treatment of Masseter Muscle Prominence
NCT03861936
Observational Study of Botox® Treatment for Patients With Upper Limb Adult Spasticity
NCT01387074
An Adult Spasticity Registry of OnabotulinumtoxinA Treatment
NCT01930786
A Safety and Efficacy Study of OnabotulinumtoxinA in Upper Facial Rhytides
NCT02261493
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Naïve to Botox® treatment
Initiating treatment with BOTOX® upon entry to the project.
botulinum toxin type A
There will be no protocol-mandated intervention with regard to physician treatment choice or management of patient condition once the patient is enrolled in the project.
Non-naïve to Botox® treatment
Receiving ongoing treatment with BOTOX® upon entry to the project.
botulinum toxin type A
There will be no protocol-mandated intervention with regard to physician treatment choice or management of patient condition once the patient is enrolled in the project.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
botulinum toxin type A
There will be no protocol-mandated intervention with regard to physician treatment choice or management of patient condition once the patient is enrolled in the project.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient (and/or patient's authorized legal representative) should provide written informed consent; a patient under the age of 18 must review and sign the Patient Assent Form
* Patients at the age of or over 14
Exclusion Criteria
* Patient with any contraindications to use botulinum toxin A
14 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Allergan
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director
Role: STUDY_DIRECTOR
Allergan
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Toronto, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AGN/MMC B00705
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.